Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Argus Health
Mallinckrodt
Johnson and Johnson
AstraZeneca
Federal Trade Commission

Generated: July 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,377,933

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,377,933 protect, and when does it expire?

Patent 8,377,933 protects LETAIRIS and is included in one NDA.

This patent has fifteen patent family members in thirteen countries.

Summary for Patent: 8,377,933
Title:Method for treating a pulmonary hypertension condition
Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
Inventor(s): Gerber; Michael J. (Denver, CO), Dufton; Christopher (Nederland, CO)
Assignee: Gilead Colorado, Inc. (Westminster, CO)
Application Number:13/162,137
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,377,933
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,377,933

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-001 Jun 15, 2007 AB RX Yes No ➤ Sign Up ➤ Sign Up FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL ➤ Sign Up
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-002 Jun 15, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
Federal Trade Commission
Colorcon
Argus Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.